Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Health Policy

PDB40 Economic Analysis of Diabetes Treatment Goals Defined by Polish Diabetes Association: How Much Does Cost-Effective Treatment Cost?

Value in Health

English

Cost Minimization Analysis for the Treatment of Primary Immunodeficiency Disease (Pidd) in the Mexican Social Security Institute in 2016

English

BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors

English

Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting

English

Pcn377 - Response Shift Effect on Quality of Life in Randomized Control Trial of Taxane Versus S-1 for Metastatic Breast Cancer Patients (Select-Bc): Structural Equation Modeling

English

Descriptive Analysis of Patients Initiating Regorafenib Therapy

English

Budget Impact Analysis of Adding Dapaglifozin to the Therapy of Diabetes Mellitus Type 2 in Bulgaria

English

Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension–symptoms and Impact (PAH-SYMPACT) Questionnaire

English

Pmu122 - Patient-Reported Outcomes on Perceived Well-Being Among Patients on Anti-Inflammatory Treatment

English

Prm237 - Performance of Propensity Score Matching in Small Samples - Simulation Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Health Policy

PDB40 Economic Analysis of Diabetes Treatment Goals Defined by Polish Diabetes Association: How Much Does Cost-Effective Treatment Cost?

Cost Minimization Analysis for the Treatment of Primary Immunodeficiency Disease (Pidd) in the Mexican Social Security Institute in 2016

BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors

Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting

Pcn377 - Response Shift Effect on Quality of Life in Randomized Control Trial of Taxane Versus S-1 for Metastatic Breast Cancer Patients (Select-Bc): Structural Equation Modeling

Descriptive Analysis of Patients Initiating Regorafenib Therapy

Budget Impact Analysis of Adding Dapaglifozin to the Therapy of Diabetes Mellitus Type 2 in Bulgaria

Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension–symptoms and Impact (PAH-SYMPACT) Questionnaire

Pmu122 - Patient-Reported Outcomes on Perceived Well-Being Among Patients on Anti-Inflammatory Treatment

Prm237 - Performance of Propensity Score Matching in Small Samples - Simulation Study